Table 1 Analysis of the association between expression of hsa-miR-4634 and clinicopathological features of NSCLC (n = 323).
Clinicopathological features (n) | hsa-miR-4634 | ||
|---|---|---|---|
Low expression (%) | High expression (%) | P-value | |
Age (years) | |||
≤ 55 (n = 146) | 68 (46.6%) | 78 (53.4%) | 0.094 |
> 55 (n = 177) | 99(55.9%) | 78 (44.1%) | |
Gender | |||
Male (n = 240) | 117 (48.8%) | 123 (51.3%) | 0.071 |
Female (n = 83) | 50 (60.2%) | 33 (39.8%) | |
Histological types | |||
ADC (n = 162) | 88 (54.3%) | 74 (45.7%) | 0.345 |
SCC (n = 161) | 79 (49.1%) | 82 (50.9%) | |
LNM status | |||
NO LNM (n = 128) | 57 (44.5%) | 71 (55.5%) | 0.037* |
LNM (n = 195) | 110 (56.4%) | 85 (43.6%) | |
Differentiation | |||
Well/Moderate (n = 150) | 73 (48.7%) | 77 (51.3%) | 0.309 |
Poor (n = 173) | 94 (54.3%) | 79 (45.7%) | |
Clinical stages | |||
Stage I and II (n = 167) | 84 (50.3%) | 83 (49.7%) | 0.602 |
Stage III (n = 156) | 83 (53.2%) | 73 (46.8%) | |
Survival status | |||
Alive (n = 210) | 100 (47.6%) | 110 (52.4%) | 0.045* |
Dead (n = 113) | 67 (59.3%) | 46 (40.7%) | |
